Cancers · 2019 · 40 citations · 31 references
MedicineOncologyPharmacologyCancer PharmacologyOncology PharmacotherapyPharmacokinetics Of Anticancer AgentsDose Adjustment In OncologyHepatocellular Carcinoma PharmacotherapyResponse AssessmentTherapy Response AssessmentHepatocellular Carcinoma TreatmentLiver Tumor TherapyMedian Effective DosePost-treatment Response AssessmentRelative Dose IntensitySorafenib TherapyTotal DoseTumor Response Evaluation
BACKGROUND: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. METHODS: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated. RESULTS: The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240-3360 mg), and the median 1M-RDI was 61.9% (7.1%-100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08-0.48, p = 0.0004 and HR 0.2, 95% CI 0.08-0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06-0.55, p = 0.002) and hand-foot skin reaction (HR 0.03, 95% CI 0.008-0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression. CONCLUSION: A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice.
31
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations
Medicine, Oncology, Pharmacotherapy +11